Hereditary transthyretin (hATTR) amyloidosis is a rare disease that runs in families. It is caused by the buildup of toxic proteins called amyloid fibrils throughout the body. The amyloid fibrils ...

Promising therapies aim to treat hATTR and improve quality of life Medically reviewed by Stella Bard, MD Hereditary transthyretin amyloidosis, or hATTR, is a rare disease that causes proteins to ...

NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.

Amvuttra is used in adults to treat polyneuropathy (nerve damage) related to hereditary amyloid transthyretin-mediated (hATTR) amyloidosis. This is a rare genetic (inherited) condition that causes ...

NICE has reversed its stance on Alnylam’s gene-silencing drug Onpattro for rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), backing NHS funding. hATTR is an ultra ...